Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
2016; Elsevier BV; Volume: 128; Issue: 5 Linguagem: Inglês
10.1182/blood-2016-01-693879
ISSN1528-0020
AutoresKlaus H. Metzeler, Tobias Herold, Maja Rothenberg‐Thurley, Susanne Amler, Maria C. Sauerland, Dennis Görlich, Stephanie Schneider, Nikola P. Konstandin, Annika Dufour, Kathrin Bräundl, Bianka Ksienzyk, Evelyn Zellmeier, Luise Hartmann, Philipp A. Greif, Michael Fiegl, Marion Subklewe, Stefan K. Bohlander, Utz Krug, Andreas Faldum, Wolfgang E. Berdel, Bernhard Wörmann, Thomas Büchner, Wolfgang Hiddemann, Jan Braess, Karsten Spiekermann,
Tópico(s)Multiple Myeloma Research and Treatments
ResumoKey Points We present comprehensive information on genetic driver events in a uniformly treated cohort of 664 adult AML patients aged 18 to 86 years. Mutations in NPM1, FLT3, CEBPA, TP53, and, in patients <60 years, DNMT3A and RUNX1, are the most important molecular risk factors in AML.
Referência(s)